metadata toggle
Clinical particulars
Target species
Pigs and sows
Indications for use
Pigs:
Active immunisation of pigs to reduce typical lesions of Glässer’s disease caused by G. parasuis serotype 5.
Onset of immunity: 2 weeks after completion of vaccination.
Duration of immunity: 14 weeks after completion of vaccination.
Sows:
For passive immunisation of the progeny of vaccinated sows and gilts to reduce infection, mortality, clinical signs and typical lesions of Glässer disease caused by G. parasuis serotype 5 and to reduce clinical signs and mortality caused by G. parasuis serotype 4.
Onset of immunity: After birth and sufficient uptake of colostrum.
Duration of immunity: 4 weeks of age against serotype 4 and at 6 weeks of age against serotype 5.
Contraindications
None.
Special warnings for each target species
Vaccinate only healthy animals.
Special precautions for use
None.
Operator warnings
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions
Pigs:
Very common (>1 animal / 10 animals treated):
Elevated temperature1, Discomfort2, Decreased activity2, Depression2, Injection site swelling3, Injection site reddening3
Common (1 to 10 animals / 100 animals treated):
Vomiting2
Very rare (<1 animal / 10.000 animals treated, including isolated reports):
Anaphylactic-type reaction4
1 ≤ 2 °C.
2 May occur on the day of vaccination. The next day returning to normal.
3 Painless reddish swellings of 2.5 ‑ 7.5 cm 3 days after vaccination.
4 In the event of anaphylactic reaction consult your veterinarian. In such cases appropriate treatment should be administered without delay.
Sows:
1 Mean 0.9 °C, with individual animals displaying a temperature increase of above 2 °C.
2 May be observed 1 to 2 days after vaccination. All animals return to normal within 1 to 3 days after vaccination.
3 Mostly non-painful swellings < 10 cm in diameter. In some cases, swelling may be warm, red, and painful > 10 cm in diameter.
4 These reactions disappear or clearly diminish 14 days after vaccination.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy or lactation
Pregnancy:
Can be used during pregnancy.
Interactions
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
Intramuscular use. Allow vaccine to reach ambient temperature. Shake well before use.
Administer 2 ml (one dose) of the vaccine intramuscularly in the neck.
Vaccination scheme pigs:
Vaccinate pigs of at least five weeks of age twice with an interval of two weeks.
Vaccination scheme sows:
Vaccinate sows at 6 to 8 weeks before expected time of farrowing twice with an interval of four weeks.
Revaccination scheme sows:
For sows vaccinated during the previous pregnancy, a single revaccination at 4 to 2 weeks before farrowing is recommended.
Overdose
Pigs:
After vaccination with a twofold overdose, reactions are not different from those after the single dose.
Sows:
After vaccination with a twofold overdose, a transient increase in temperature may occur (mean 1.8 °C, with a maximum observed temperature of 41.3 °C). Other reactions are not different from those after a single dose.
Withdrawal period
Zero days.